As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...

New research published in the American Journal of Health-System Pharmacy suggests a possible link between the GLP-1 drug ...

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

GLP-1 medications like semaglutide and tirzepatide have exploded in popularity, with millions of Americans turning to them for weight loss. But are they the magic bullet for sustainable results? The ...

Social media users are accusing the US ambassador to Israel, Mike Huckabee, of admitting that the US and Israel are using starvation as a "weapon" in Gaza. Last Friday, the head of World Health ...

Mounjaro and Wegovy are two of the biggest names in the world of weight-loss drugs but it's been unclear which is more ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...